Skip to main content
Report forecasts biosimilar sales to top $6.5B in 2024

A report from S&P Global Ratings predicts biosimilar sales will increase nearly threefold to over $6.5 billion in 2024 from around $2.5 billion last year. Biosimilars are expected to make up 2.5% of overall biopharmaceutical sales by 2024, according to the analysis, which didn't include sales from Novartis' Sandoz unit, meaning the estimates might be low.

Full Story: